ORY 3001
Alternative Names: ORY-3001Latest Information Update: 25 Mar 2024
At a glance
- Originator Oryzon
- Class Antianaemics; Small molecules
- Mechanism of Action Lysine specific demethylase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Sickle cell anaemia
Most Recent Events
- 20 Feb 2024 Preclinical trials in Sickle cell anaemia in Spain (PO) (Oryzon Genomics pipeline, February 2024)